Financial News

Date	Title
08/11/22	National Cancer Center Hospital in Tokyo Upgrades to MRIdian® Linac for MRI-Guided Radiation Therapy and has treated its first patients PDF Version
08/08/22	ViewRay Selects Denver for Headquarters PDF Version
08/02/22	ViewRay Announces Second Quarter 2022 Results PDF Version
08/02/22	ViewRay and Katie Couric Media Partner to Raise Awareness about MRIdian® MRI-Guided Radiation Therapy PDF Version
07/29/22	Centre Oscar Lambret Selects ViewRay's MRIdian® MRI-Guided Radiation Therapy System PDF Version
07/20/22	Miami Cancer Institute First in World to Deliver Adaptive MR-Guided Radiation Therapy with the MRIdian® A3i System
07/19/22	Saitama Medical University International Medical Center Selects MRIdian® MRI-Guided Radiation Therapy System PDF Version
07/19/22	ViewRay Announces Conference Call for Second Quarter 2022 Financial Results to be Held After Market on August 2, 2022 PDF Version
06/09/22	VA Ann Arbor Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services PDF Version
06/07/22	Shin-Matsudo Central General Hospital Select's ViewRay's MRIdian® MRI-Guided Radiation Therapy System to Expand Access to Precision Radiation Therapy PDF Version
06/02/22	Henry Ford Health Becomes the First Center to Treat Patients with ViewRay's MRIdian A3i System PDF Version
05/10/22	Clinical Value of MRIdian® MRI-Guided Radiation Therapy in the Treatment of Ultracentral/Central Lung Tumors Presented at ESTRO 2022 PDF Version
05/06/22	MRIdian Clinical and Research Experience Featured in Nearly 40 Abstracts at ESTRO 2022, the Leading European Radiation Oncology Meeting PDF Version
05/05/22	ViewRay Announces First Quarter 2022 Results PDF Version
05/05/22	ViewRay Named “Best Overall MedTech Company” in 2022 MedTech Breakthrough Awards Program
05/03/22	UCI Health Adopts ViewRay® MRIdian® MRI-Guided Radiation Therapy System PDF Version
04/21/22	ViewRay Announces Conference Call for First Quarter 2022 Financial Results to be Held After Market on May 5, 2022 PDF Version
03/15/22	University Hospital Agostino Gemelli Treats its 1,000th Patient Using MRIdian® MRI-Guided Radiation Therapy PDF Version
03/10/22	ViewRay to Host a Virtual Clinical Data Event for Investors and Analysts on March 16, 2022 PDF Version
03/10/22	First Toxicity Results from SCIMITAR Prospective Phase II Trial Signal Favorable Toxicity Profile of Post-Prostatectomy Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer PDF Version
03/09/22	ViewRay Enters into Cooperation Agreement with Hudson Executive Capital PDF Version
03/03/22	Acibadem Group Purchases Second MRIdian® System for Acibadem Altunizade Hospital in Istanbul PDF Version
02/24/22	ViewRay Announces Fourth Quarter and Full Year 2021 Results PDF Version
02/15/22	Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer PDF Version
02/10/22	ViewRay® to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference PDF Version
02/10/22	ViewRay Announces Conference Call for Fourth Quarter and Full Year 2021 Financial Results to be Held After Market on February 24, 2022 PDF Version
02/09/22	University Hospital Halle (Saale) Selects ViewRay's MRIdian® System to Broaden Advanced Radiation Therapy Treatment Services PDF Version
01/25/22	ViewRay® to Participate in the B. Riley Securities Oncology Conference PDF Version
01/10/22	ViewRay Announces Preliminary Fourth Quarter and Full Year 2021 Results PDF Version

(Common Stock)
Exchange	(US Dollar)
Price
Change (%)
Volume

Investor Relations

Financial News

Stock Quote

E-mail Alerts

Language Select